Transgene Biotek Ltd
Transgene Biotek Ltd (TRABI) last traded at ₹2.88, a market capitalisation of ₹21.8 crore. Over the past 52 weeks the stock has ranged between ₹1.83 and ₹4.5. Transgene Biotek Ltd last reported results for the quarter ended Jun 2026, with sales of ₹0.06 crore and net profit of ₹-0.39 crore. Figures are as of 25 Aug 2026 and are not real time.
Transgene Biotek Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Transgene Biotek Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.06 cr, up 20.0% from ₹0.05 cr a year earlier. Net profit was ₹-0.39 cr, up 9.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.08 | 0.08 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 |
| Expenses | 0.13 | 0.17 | 0.62 | 0.18 | 0.13 | 0.1 | 0.33 | 0.12 |
| Operating profit | -0.07 | -0.09 | -0.54 | -0.13 | -0.08 | -0.05 | -0.28 | -0.06 |
| OPM % | -116.67% | -112.50% | -675.00% | -260.00% | -160.00% | -100.00% | -560.00% | -100.00% |
| Other income | 0.04 | 0.04 | 0.04 | 0 | 0 | 0 | 0.15 | 0 |
| Interest | 0.02 | 0.02 | 0.19 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 |
| Profit before tax | -0.07 | -0.09 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 | -0.39 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.07 | -0.09 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 | -0.39 |
| EPS (₹) | -0.01 | -0.01 | -0.09 | -0.06 | -0.05 | -0.05 | -0.06 | -0.05 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Transgene Biotek Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | 0.21 | 0.21 |
| Operating profit | -0.53 | -0.46 | -0.62 | -0.6 | -1.12 | -0.54 | -0.47 |
| OPM % | -311.76% | -511.11% | -1,033.33% | -260.87% | -430.77% | -257.14% | -223.81% |
| Net profit | -10.43 | -10.4 | -6.01 | -0.66 | -0.68 | -1.65 | -1.61 |
| EPS (₹) | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.22 | -0.21 |
TTM is the trailing twelve months to the most recent quarter.
Transgene Biotek Ltd growth and returns
- 10 Years
- 2%
- 5 Years
- 4%
- 3 Years
- 52%
- TTM
- -22%
- 10 Years
- 7%
- 5 Years
- 13%
- 3 Years
- 20%
- TTM
- -24%
- 10 Years
- 4%
- 5 Years
- -4%
- 3 Years
- -13%
- 1 Year
- -31%
- 10 Years
- -23%
- 5 Years
- -30%
- 3 Years
- -10%
- Last Year
- -18%
Transgene Biotek Ltd shareholding pattern
Promoters held 23.64% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
| Public | 76.37% | 76.37% | 76.38% | 76.37% | 76.37% | 76.37% | 76.37% | 76.37% |
| No. of shareholders | 12,963 | 13,307 | 13,583 | 13,475 | 13,461 | 13,545 | 13,767 | 13,817 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Transgene Biotek Ltd corporate filings
- Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Transgene Biotek Ltd has issued a mandatory newspaper publication regarding the…
Read the full analysis - Sub: Outcome of the Meeting of the Board of Directors held on August 07, 2026. This has reference to our letter dated 22nd July 2026, Intimating the meeting of the Board of Directors of ....Board Meetinglow impact
Cruxal's analysis: Transgene Biotek Limited reported a net loss of 38.90 lakh for the quarter ended 30th…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Transgene Biotek Ltd
Cruxal reads every Transgene Biotek Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.